Digests

August 2026

This Month in Ovarian Cancer Research

The month sat with treatments already in wide use. The final quality-of-life analysis from a major PARP inhibitor trial found maintenance itself did not make people feel worse than placebo, while recurrence did, and that decline never fully reversed. Antibody-drug conjugates stayed the most active area in recurrent disease, and two studies asked who is left out of the evidence.

August 2026

This Month in Cervical Cancer Research

Most of the month's work was about why prevention is not reaching everyone. A network meta-analysis found one- and two-dose HPV schedules retain meaningful protection, which matters where three doses are unaffordable, and studies from Finland and Mexico showed HPV type, not just HPV status, sharpens who needs colposcopy now.

August 2026

This Month in Uterine Cancer Research

A month about refining decisions rather than adding new ones. Pooled trial data concluded tumor grade no longer needs to guide treatment planning in MMR-deficient disease, and two teams disagreed outright on checking lymph nodes during surgery for precancer. Adding a second drug to immunotherapy maintenance delayed progression without extending life.

August 2026

This Month in Vaginal & Vulvar Cancer Research

Both digests led with prevention: a global modelling study put the vaginal and vulvar cancer HPV vaccination could prevent in lower-income countries in the millions, while a systematic review found uptake stalls on knowledge and trust as much as cost. Vulvar work centered on the disease's two separate origins, HPV and chronically inflamed skin.